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SUMARY
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Several randomized triais have provided
evidence supporting the efficacy of conventional
radiation therapy in the management of
malignant gliomas. In this paper a review of
different radiotherapeutic modalities including
non conventional regiments of irradiation, use of
radiosensitizers, boron neutron capture therapy,
stereotactic radiosurgery and brachytherapy is
presented.
INTRODUCTION
High grade (III and IV) malignant gliomas are
the most common primary brain tumours in
adults. It is a devastating illness : cures are rare
and more than 50% of patients die within 12
months. The median survival time for patients
with anaplastic astrocytoma is 36 months, and
for patients with glioblastoma multiforme, who
make up 80% of those accrued to cooperative
group studies is 10 months, whereas the 3-year
survival rate is only 6% (Leibel et al. 1994).
Standard treatment for malignant gliomas
begins with surgical intervention folIowed by
irradiation. The role of ehemotherapy remains
controversial (Graham 1993). For reasons which
are not elear, malignant gliomas do not
metastasize to distant organs except very rarely,
and the pattern of failure is local tumour
recurrence. Unfortunately, the method to
overcome this resistance to local treatment is
not known. Various means have been tried to
improve the effectiveness of radiation therapy.
Such attempts include the use of non
conventional regimens of irradiation, neutron
therapy, radiation sensitizers, stereotactic
external beam irradiation and interstitial
brachytherapy.
TOTALDOSE AND TREATMENT VOLUME
Salazar et al. (1979) have presented the use
of unusually high doses of irradiation in patients
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suffering from malignant gliomas. Compared
with a conventional dose (50 Gy), his treatment
with up to 75-80 Gy produced an increased
survival for both grade III and IV patients, but
the gain was limited and only maintained for two
years in grade IV gliomas, and for four years in
grade III. Walker et al. (1979) have reported a
significant relationship between dose and
survival in 621 patients with malignant gliomas :
the greater the dose, the greater median
survival (MS). The MS for patients treated with
the dose of 50 Gy and 60 Gy were respectively
7 months and 11 months, but this difference
was upheld for only a limited time of two years.
A retrospective analysis of 178 patients
presented by Shibamoto et al. (1990) showed
that the radiation dose did not appear to
influence significantly long term survival.
The widely infiltrating nature of high grade
gliomas has encouraged radiotherapiststo treat
large tissue volumes (Bloom 1982), but since
failure in these tumours is invariably a result of
recurrence in the primary site, the value of
routine whole brain irradiation is questionable
(Hess et al. 1994, Shapiro et al. 1989).
UNCONVENTIONAL IRRADIATION
Due to the disappointing results with
conventional radiation therapy, different
treatment alternatives have been explored.
Multiple daily fractions have been used in
attempt to increase tumour control and spare
normai tissues. Hyperfractionation consists in
giving multiple daily fractions in smaller than
conventional doses, but reaching a therapeutic
dose in a treatment period simiJar to
conventional schedules. Accelerated
fractionation involves giving 2 or 3 doses per
day to a therapeutic dose resulting in a short
overall treatment time. The theoretical
advantages of using multiple daily fractions are
alpha type celi killing, slow tumour repopulation,
and enhaneement of normai tissue tolerance
(Thames et al. 1983). Results of postoperative
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TABLE 1. Results ot postoperative multiple daily fractionated
radiation therapy of malignant gliomas.
multiple daily fractionated radiation therapy are
presented in table 1.
Majority of patients with malignant gliomas die
of progressive disease, largely palliative
treatment should be considered for them. Every
such treatment for poor prognosis patients must
be able to demonstrate effectiveness in terms of
palliation and should be short, well tolerated,
non-toxic as well as acceptable to patients and
careers. In this view, several studies of
hypofractionated irradiation were proposed, and
their results are summarized in table 2.
AF : accelerated tractionation
HF : hyperfractionation
MST : mean survival time
No ot
patients
STEREOTACTIC RADIOSURGERY
BNCT is a binary treatment (the basic concept
is to selectively destroy malignant cells while
concomitantly sparing normai tissue) of hi~h
grade gliomas that involves incorporating 1 B
into the tumour using appropriate
pharmacological agents and then irradiating the
tumour with termai or epitermal neutron beams
(Laramore et al. 1996). One hundred twenty
patients with intracranial tumours and one
patient with extracranial nerve related tumour
were treated by standard technique of BNTC
using 10B - sodium-
mercaptoundecahydrodecarbonate. Nine
patients have Iived longer than 10 years. It can
be suggested that BNTC is a radiotherapy that
can produce "cure" of both malignant and
benign brain tumours while preserving a good
quality of life if conducted without conventional
irradiation (Hatanaka et al. 1994).
BORON NEUTRON CAPTURE THERAPY
(BNCT)
the objective to reduce the hypoxic tumour cells
compartment in malignant gliomas, there is no
evidence that the measures taken to minimise
the hypoxia had the desired effect. This has
necessitated the search for new treatment
approaches such as radiotherapy combined with
carbogen breathing and nicotynamide (in
experimental models breathing carbogen prior
to, and during irradiation helps to re-oxygenate
chronically hypoxic cells, and nicotynamide has
the ability to reduce acute hypoxia).
Unfortunately these studies have met with Iittle
success (Van der Maazen et al. 1995, Rojas et
al. 1992).
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TABLE 2. Results ot postoperative hypofractionated
radiation
therapy ot malignant gliomas.
RADIOSENSITIZERS
Relative radioresistance of malignant gliomas
is believed to be associated with the presence
of hypoxic potentially viable tumor cells. Clinical
efforts to sterilize these "radioresistant" cells
have focused on radiation using hyperbaric
oxygen, radiosensitizers such as electron affinic
drugs (metronidazole, misonidazole),
halogenated deoxyuridines (iododeoxyuridine,
bromodeoxyuridine) and high Iinear energy
transfer radiation (Chang et al. 1977, Urtasun et
al. 1976, Bleehen et al. 1981, Jackson et al.
1987, Catteral et al. 1980, Castro et al. 1997,
Pickies et al. 1997). Of all clinical studies with
Stereotactic radiosurgery has historically been
used for arteriovenous malformations and
benign tumours, but have recently been upheld
as a tool in the multimodality management of
intracranial malignancies. In selected patients
with smali, relatively spherical high grade
gliomas, radiosurgery appears to produce
tumuor control, survival, and toxicity similar to
that of brachytherapy (Flickinger et al. 1994). A
total of 115 patients were treated with a
combination of surgery, external beam radiation
therapy, and linac-based radiosurgery. The
actuarial 2-year and median survival for all
patients analyzed was 45% and 96 weeks,
respectively. In comparison with the results from
a previously published analysis of 1578 patients
entered on three RTOG external beam radiation
protocols, those patients treated with
radiosurgery had a significantly improved 2-year
and median survival (Sarkaria et al. 1995).
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BRACHYTHERAPY
The rationale for the brain implant is that
interstitial irradiation can deliver a large dose to
the tumour volume while sparing surrounding
normai tissues. Unfortunately, only 20-30% of
patients are eligible to receive implantation on
the size and disposition at the tumour as well as
the general condition of the patient (Loeffler et
al. 1990). Since the early 1950s the effect of
brachytherapy on intracranial tumours by direct
interstitial or intracavitary implanting of
radioactive isotopes could first be
demonstrated only in smali volume tumours or
cysts : in some cases the effect was even
curative. This therapy has only become possible
by using stereotactic operations methods. A
total of 307 patients with glioma were treated
with high-activity removable iodine-125
interstitial brain implants at the UCSF. Recurrent
gliomas underwent brain implant alone, whereas
previously untreated tumours underwent brain
implant after external beam radiotherapy. Of
these patients, 106 had primary and 67 had
recurrent glioblastoma multiforme. Median
survival time for those patients was 22 months
and 12 months respectively. This study
demonstrates that interstitial implant is well-
tolerated and prolongs survival in patients with
primary and recurrent gliobastoma, as
evidenced by the 3-year survival rates of
22% and 15%, respectively (Scharfen et al.
1992).
CONCLUSIONS
Malignant gliomas are essentially localized
tumours that have defied most treatment.
Surgical resection results in a median survival of
six months, postoperative conventional
irradiation may increase survival by as much as
100%. Evidence of improvement in survival was
observed neither in patients receiving multiple
daily fractionated irradiation, nor in patients for
whom radiation sensitizers such as
nitroimidazole compounds or halogenated
pyrymidine analogs were associated to radiation
therapy.
Hypofractionated schedules have a rather
palliative role in the management of malignant
gliomas.
Combination of full-dose external beam
radiotherapy and brachytherapy or radiosurgery
boost in selected patients with malignant
gliomas leads to an increase in median survival,
while external beam irradiation alone in patients
with similar prognosis does not.
No therapeutically beneficial effect of high
linear energy transfer irradiation was observed.
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It is evident that malignant gliomas cannot be
eradicated by presently available
radiotherapeutic techniques, and stil! present a
supreme challenge to local modes of therapy.
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